Skip to main
LPCN

Lipocine (LPCN) Stock Forecast & Price Target

Lipocine (LPCN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lipocine Inc. is advancing its pharmaceutical pipeline with promising data from LPCN 1154, an oral formulation of brexanolone, which exhibits improved efficacy and safety characteristics compared to zuranolone, including a rapid onset of action and a substantial remission rate of 61% by Day 3. The company's approach to drug delivery through proprietary technology positions it favorably within the biopharmaceutical landscape, with implications for future regulatory approvals, as evidenced by its plans to submit a 505(b)(2) new drug application based on the positive topline data. Despite a reported net loss of $3.2 million, the increase in the probability of LPCN 1154's approval to 50% reflects optimism about its potential market impact and the overall strategic direction of Lipocine.

Bears say

Lipocine Inc. reported a net loss of $3.2 million in the third quarter of 2025, highlighting ongoing financial challenges as the company continues its focus on research and development. The company faces multiple risks related to its product pipeline, particularly concerning LPCN 1154, including potential failures in clinical trials, regulatory approval, and market competition that could impact commercial success. Additionally, the threat of dilution presents further financial concerns that could negatively affect shareholder value and confidence.

Lipocine (LPCN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lipocine and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lipocine (LPCN) Forecast

Analysts have given Lipocine (LPCN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Lipocine (LPCN) has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lipocine (LPCN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.